Methyl-CpG-binding domain proteins: Readers of the epigenome

Epigenomics

Volumn 7, Issue 6, 2015, Pages 1051-1073

  Du, Qian ^a   Luu, Phuc Loi ^a   Stirzaker, Clare ^a,b   Clark, Susan J ^a,b  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

cancer; DNA methylation; epigenetics; MBD1; MBD2; MBD3; MBD4; MeCP2; methyl binding domain proteins

Indexed keywords

BAZ2 PROTEIN; HISTONE DEACETYLASE; METHYL CPG BINDING PROTEIN; METHYL CPG BINDING PROTEIN 1; METHYL CPG BINDING PROTEIN 2; METHYL CPG BINDING PROTEIN 3; METHYL CPG BINDING PROTEIN 4; METHYL CPG BINDING PROTEIN 5; METHYL CPG BINDING PROTEIN 6; SETDB PROTEIN; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; PROTEIN BINDING;

CHROMATIN ASSEMBLY AND DISASSEMBLY; DEACETYLATION; DNA METHYLATION; EPIGENETICS; GENE MUTATION; GENE REPRESSION; HEARING IMPAIRMENT; HETEROCHROMATIN; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; NEOPLASM; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN FAMILY; REVIEW; ANIMAL; BINDING SITE; CELL DIFFERENTIATION; CHEMISTRY; CPG ISLAND; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MULTIGENE FAMILY; MUTATION; NUCLEAR REPROGRAMMING;

ANIMALS; BINDING SITES; CELL DIFFERENTIATION; CELLULAR REPROGRAMMING; CPG ISLANDS; DNA METHYLATION; DNA-BINDING PROTEINS; DOWN-REGULATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MULTIGENE FAMILY; MUTATION; NEOPLASMS; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS;

EID: 84945946611     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.15.39     Document Type: Review

References (197)

1. Bestor T, Laudano A, Mattaliano R, Ingram V. Cloning and sequencing of a cDNA encoding DNA methyltransferase of mouse cells. The carboxyl-terminal domain of the mammalian enzymes is related to bacterial restriction methyltransferases. J. Mol. Biol. 203(4), 971-983 (1988).
2. Stirzaker C, Taberlay PC, Statham AL, Clark SJ. Mining cancer methylomes: prospects and challenges. Trends Genet. 30(2), 75-84 (2014).
3. Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J. Mol. Biol. 196(2), 261-282 (1987).
4. Ogoshi K, Hashimoto S, Nakatani Y et al. Genome-wide profiling of DNA methylation in human cancer cells. Genomics 98(4), 280-287 (2011).
5. Ball MP, Li JB, Gao Y et al. Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat. Biotechnol. 27(4), 361-368 (2009).
6. Taberlay PC, Statham AL, Kelly TK, Clark SJ, Jones PA. Reconfiguration of nucleosome-depleted regions at distal regulatory elements accompanies DNA methylation of enhancers and insulators in cancer. Genome Res. 24(9), 1421-1432 (2014).
7. Okano M, Xie S, Li E. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat. Genet. 19(3), 219-220 (1998).
8. Bogdanovic O, Veenstra GJ. DNA methylation and methyl-CpG binding proteins: developmental requirements and function. Chromosoma 118(5), 549-565 (2009).
9. Hashimoto H, Vertino PM, Cheng X. Molecular coupling of DNA methylation and histone methylation. Epigenomics 2(5), 657-669 (2010).
10. Filion GJ, Zhenilo S, Salozhin S, Yamada D, Prokhortchouk E, Defossez PA. A family of human zinc finger proteins that bind methylated DNA and repress transcription. Mol. Cell. Biol. 26(1), 169-181 (2006).
11. Unoki M, Nishidate T, Nakamura Y. ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain. Oncogene 23(46), 7601-7610 (2004).
12. Prokhortchouk A, Hendrich B, Jorgensen H et al. The p120 catenin partner Kaiso is a DNA methylation-dependent transcriptional repressor. Genes Dev. 15(13), 1613-1618 (2001).
13. Hendrich B, Bird A. Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol. Cell. Biol. 18(11), 6538-6547 (1998).
14. Pastor WA, Aravind L, Rao A. TETonic shift: biological roles of TET proteins in DNA demethylation and transcription. Nat. Rev. Mol. Cell Biol. 14(6), 341-356 (2013).
15. Baymaz HI, Fournier A, Laget S et al. MBD5 and MBD6 interact with the human PR-DUB complex through their methyl-CpG-binding domain. Proteomics 14(19), 2179-2189 (2014).
16. Hendrich B, Tweedie S. The methyl-CpG binding domain and the evolving role of DNA methylation in animals. Trends Genet. 19(5), 269-277 (2003).
17. Nan X, Meehan RR, Bird A. Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2. Nucleic Acids Res. 21(21), 4886-4892 (1993).
18. Ohki I, Shimotake N, Fujita N et al. Solution structure of the methyl-CpG binding domain of human MBD1 in complex with methylated DNA. Cell 105(4), 487-497 (2001).
19. Boeke J, Ammerpohl O, Kegel S, Moehren U, Renkawitz R. The minimal repression domain of MBD2b overlaps with the methyl-CpG-binding domain and binds directly to Sin3A. J. Biol. Chem. 275(45), 34963-34967 (2000).
20. Wade PA, Gegonne A, Jones PL, Ballestar E, Aubry F, Wolffe AP. Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nat. Genet. 23(1), 62-66 (1999).
21. Ng HH, Jeppesen P, Bird A. Active repression of methylated genes by the chromosomal protein MBD1. Mol. Cell. Biol. 20(4), 1394-1406 (2000).
22. Meehan RR, Lewis JD, Bird AP. Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA. Nucleic Acids Res. 20(19), 5085-5092 (1992).
23. Fuks F, Hurd PJ, Wolf D, Nan X, Bird AP, Kouzarides T. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J. Biol. Chem. 278(6), 4035-4040 (2003).
24. Nan X, Ng HH, Johnson CA et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393(6683), 386-389 (1998).
25. Kernohan KD, Vernimmen D, Gloor GB, Berube NG. Analysis of neonatal brain lacking ATRX or MeCP2 reveals changes in nucleosome density, CTCF binding and chromatin looping. Nucleic Acids Res. 42(13), 8356-8368 (2014).
26. Agarwal N, Hardt T, Brero A et al. MeCP2 interacts with HP1 and modulates its heterochromatin association during myogenic differentiation. Nucleic Acids Res. 35(16), 5402-5408 (2007).
27. Dhasarathy A, Wade PA. The MBD protein family-reading an epigenetic mark? Mutat. Res. 647(1-2), 39-43 (2008).
28. Maunakea AK, Chepelev I, Cui K, Zhao K. Intragenic DNA methylation modulates alternative splicing by recruiting MeCP2 to promote exon recognition. Cell Res. 23(11), 1256-1269 (2013).
29. Amir RE, Van Den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 23(2), 185-188 (1999).
30. D'esposito M, Quaderi NA, Ciccodicola A et al. Isolation, physical mapping, and northern analysis of the X-linked human gene encoding methyl CpG-binding protein, MECP2. Mamm. Genome 7(7), 533-535 (1996).
31. Shahbazian MD, Antalffy B, Armstrong DL, Zoghbi HY. Insight into Rett syndrome: MeCP2 levels display tissueand cell-specific differences and correlate with neuronal maturation. Hum. Mol. Genet. 11(2), 115-124 (2002).
32. Kokura K, Kaul SC, Wadhwa R et al. The Ski protein family is required for MeCP2-mediated transcriptional repression. J. Biol. Chem. 276(36), 34115-34121 (2001).
33. Lyst MJ, Ekiert R, Ebert DH et al. Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT co-repressor. Nat. Neurosci. 16(7), 898-902 (2013).
34. Jones PL, Veenstra GJ, Wade PA et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet. 19(2), 187-191 (1998).
35. Ballas N, Grunseich C, Lu DD, Speh JC, Mandel G. REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis. Cell 121(4), 645-657 (2005).
36. Lunyak VV, Burgess R, Prefontaine GG et al. Corepressordependent silencing of chromosomal regions encoding neuronal genes. Science 298(5599), 1747-1752 (2002).
37. Harikrishnan KN, Chow MZ, Baker EK et al. Brahma links the SWI/SNF chromatin-remodeling complex with MeCP2-dependent transcriptional silencing. Nat. Genet. 37(3), 254-264 (2005).
38. Kimura H, Shiota K. Methyl-CpG-binding protein, MeCP2, is a target molecule for maintenance DNA methyltransferase, DNMT1. J. Biol. Chem. 278(7), 4806-4812 (2003).
39. Kernohan KD, Jiang Y, Tremblay DC et al. ATRX partners with cohesin and MeCP2 and contributes to developmental silencing of imprinted genes in the brain. Dev. Cell 18(2), 191-202 (2010).
40. Mellen M, Ayata P, Dewell S, Kriaucionis S, Heintz N. MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system. Cell 151(7), 1417-1430 (2012).
41. Szulwach KE, Li X, Li Y et al. 5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nat. Neurosci. 14(12), 1607-1616 (2011).
42. Vaute O, Nicolas E, Vandel L, Trouche D. Functional and physical interaction between the histone methyl transferase Suv39H1 and histone deacetylases. Nucleic Acids Res. 30(2), 475-481 (2002).
43. Villa R, Morey L, Raker VA et al. The methyl-CpG binding protein MBD1 is required for PML-RARalpha function. Proc. Natl Acad. Sci. USA 103(5), 1400-1405 (2006).
44. Fujita N, Watanabe S, Ichimura T et al. Methyl-CpG binding domain 1 (MBD1) interacts with the Suv39h1-HP1 heterochromatic complex for DNA methylationbased transcriptional repression. J. Biol. Chem. 278(26), 24132-24138 (2003).
45. Sarraf SA, Stancheva I. Methyl-CpG binding protein MBD1 couples histone H3 methylation at lysine 9 by SETDB1 to DNA replication and chromatin assembly. Mol. Cell 15(4), 595-605 (2004).
46. Ichimura T, Watanabe S, Sakamoto Y, Aoto T, Fujita N, Nakao M. Transcriptional repression and heterochromatin formation by MBD1 and MCAF/AM family proteins. J. Biol. Chem. 280(14), 13928-13935 (2005).
47. Fujita N, Watanabe S, Ichimura T et al. MCAF mediates MBD1-dependent transcriptional repression. Mol. Cell. Biol. 23(8), 2834-2843 (2003).
48. Uchimura Y, Ichimura T, Uwada J et al. Involvement of SUMO modification in MBD1-and MCAF1-mediated heterochromatin formation. J. Biol. Chem. 281(32), 23180-23190 (2006).
49. Gu P, Xu X, Le Menuet D, Chung AC, Cooney AJ. Differential recruitment of methyl CpG-binding domain factors and DNA methyltransferases by the orphan receptor germ cell nuclear factor initiates the repression and silencing of Oct4. Stem Cells 29(7), 1041-1051 (2011).
50. Le Guezennec X, Vermeulen M, Brinkman AB et al. MBD2/NuRD and MBD3/NuRD, two distinct complexes with different biochemical and functional properties. Mol. Cell. Biol. 26(3), 843-851 (2006).
51. Ramirez J, Dege C, Kutateladze TG, Hagman J. MBD2 and multiple domains of CHD4 are required for transcriptional repression by Mi-2/NuRD complexes. Mol. Cell. Biol. 32(24), 5078-5088 (2012).
52. Marhold J, Brehm A, Kramer K. The Drosophila methyl-DNA binding protein MBD2/3 interacts with the NuRD complex via p55 and MI-2. BMC Mol. Biol. 5(1), 20 (2004).
53. Brackertz M, Boeke J, Zhang R, Renkawitz R. Two highly related p66 proteins comprise a new family of potent transcriptional repressors interacting with MBD2 and MBD3. J. Biol. Chem. 277(43), 40958-40966 (2002).
54. Brackertz M, Gong Z, Leers J, Renkawitz R. p66alpha and p66beta of the Mi-2/NuRD complex mediate MBD2 and histone interaction. Nucleic Acids Res. 34(2), 397-406 (2006).
55. Sekimata M, Takahashi A, Murakami-Sekimata A, Homma Y. Involvement of a novel zinc finger protein, MIZF, in transcriptional repression by interacting with a methyl-CpG-binding protein, MBD2. J. Biol. Chem. 276(46), 42632-42638 (2001).
56. Tan CP, Nakielny S. Control of the DNA methylation system component MBD2 by protein arginine methylation. Mol. Cell. Biol. 26(19), 7224-7235 (2006).
57. Feng Q, Zhang Y. The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes. Genes Dev. 15(7), 827-832 (2001).
58. Tatematsu KI, Yamazaki T, Ishikawa F. MBD2-MBD3 complex binds to hemi-methylated DNA and forms a complex containing DNMT1 at the replication foci in late S phase. Genes Cells 5(8), 677-688 (2000).
59. Angrisano T, Lembo F, Pero R et al. TACC3 mediates the association of MBD2 with histone acetyltransferases and relieves transcriptional repression of methylated promoters. Nucleic Acids Res. 34(1), 364-372 (2006).
60. Baubec T, Ivanek R, Lienert F, Schubeler D. Methylationdependent and-independent genomic targeting principles of the MBD protein family. Cell 153(2), 480-492 (2013).
61. Gunther K, Rust M, Leers J et al. Differential roles for MBD2 and MBD3 at methylated CpG islands, active promoters and binding to exon sequences. Nucleic Acids Res. 41(5), 3010-3021 (2013).
62. Stefanska B, Suderman M, Machnes Z, Bhattacharyya B, Hallett M, Szyf M. Transcription onset of genes critical in liver carcinogenesis is epigenetically regulated by methylated DNA-binding protein MBD2. Carcinogenesis 34(12), 2738-2749 (2013).
63. Fujita H, Fujii R, Aratani S, Amano T, Fukamizu A, Nakajima T. Antithetic effects of MBD2a on gene regulation. Mol. Cell. Biol. 23(8), 2645-2657 (2003).
64. Kaji K, Caballero IM, Macleod R, Nichols J, Wilson VA, Hendrich B. The NuRD component Mbd3 is required for pluripotency of embryonic stem cells. Nat. Cell Biol. 8(3), 285-292 (2006).
65. Morey L, Brenner C, Fazi F et al. MBD3, a component of the NuRD complex, facilitates chromatin alteration and deposition of epigenetic marks. Mol. Cell. Biol. 28(19), 5912-5923 (2008).
66. Choi WI, Jeon BN, Yoon JH et al. The proto-oncoprotein FBI-1 interacts with MBD3 to recruit the Mi-2/NuRDHDAC complex and BCoR and to silence p21WAF/CDKN1A by DNA methylation. Nucleic Acids Res. 41(13), 6403-6420 (2013).
67. Aguilera C, Nakagawa K, Sancho R, Chakraborty A, Hendrich B, Behrens A. c-Jun N-terminal phosphorylation antagonises recruitment of the Mbd3/NuRD repressor complex. Nature 469(7329), 231-235 (2011).
68. Reynolds N, Salmon-Divon M, Dvinge H et al. NuRDmediated deacetylation of H3K27 facilitates recruitment of Polycomb Repressive Complex 2 to direct gene repression. EMBO J. 31(3), 593-605 (2012).
69. Whyte WA, Bilodeau S, Orlando DA et al. Enhancer decommissioning by LSD1 during embryonic stem cell differentiation. Nature 482(7384), 221-225 (2012).
70. Wang Y, Zhang H, Chen Y et al. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 138(4), 660-672 (2009).
71. Shimbo T, Du Y, Grimm SA et al. MBD3 localizes at promoters, gene bodies and enhancers of active genes. PLoS Genet. 9(12), e1004028 (2013).
72. Reynolds N, Latos P, Hynes-Allen A et al. NuRD suppresses pluripotency gene expression to promote transcriptional heterogeneity and lineage commitment. Cell Stem Cell 10(5), 583-594 (2012).
73. Yildirim O, Li R, Hung JH et al. Mbd3/NURD complex regulates expression of 5-hydroxymethylcytosine marked genes in embryonic stem cells. Cell 147(7), 1498-1510 (2011).
74. Cai Y, Geutjes EJ, De Lint K et al. The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes. Oncogene 33(17), 2157-2168 (2014).
75. Kondo E, Gu Z, Horii A, Fukushige S. The thymine DNA glycosylase MBD4 represses transcription and is associated with methylated p16(INK4a) and hMLH1 genes. Mol. Cell. Biol. 25(11), 4388-4396 (2005).
76. Bellacosa A, Cicchillitti L, Schepis F et al. MED1, a novel human methyl-CpG-binding endonuclease, interacts with DNA mismatch repair protein MLH1. Proc. Natl Acad. Sci. USA 96(7), 3969-3974 (1999).
77. Laget S, Miotto B, Chin HG et al. MBD4 cooperates with DNMT1 to mediate methyl-DNA repression and protects mammalian cells from oxidative stress. Epigenetics 9(4), 546-556 (2014).
78. Boland MJ, Christman JK. Characterization of DNMT3b:thymine-DNA glycosylase interaction and stimulation of thymine glycosylase-mediated repair by DNA methyltransferase(s) and RNA. J. Mol. Biol. 379(3), 492-504 (2008).
79. Rai K, Huggins IJ, James SR, Karpf AR, Jones DA, Cairns BR. DNA demethylation in zebrafish involves the coupling of a deaminase, a glycosylase, and gadd45. Cell 135(7), 1201-1212 (2008).
80. Cortellino S, Xu J, Sannai M et al. Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cell 146(1), 67-79 (2011).
81. Hashimoto H, Zhang X, Cheng X. Excision of thymine and 5-hydroxymethyluracil by the MBD4 DNA glycosylase domain: structural basis and implications for active DNA demethylation. Nucleic Acids Res. 40(17), 8276-8284 (2012).
82. Bienvenu T, Chelly J. Molecular genetics of Rett syndrome: when DNA methylation goes unrecognized. Nat. Rev. Genet. 7(6), 415-426 (2006).
83. Zhou Z, Qin J, Tang J et al. Down-regulation of MeCP2 in Hirschsprung's disease. J. Pediatr. Surg. 48(10), 2099-2105 (2013).
84. Carney RM, Wolpert CM, Ravan SA et al. Identification of MeCP2 mutations in a series of females with autistic disorder. Pediatr. Neurol. 28(3), 205-211 (2003).
85. Loat CS, Curran S, Lewis CM et al. Methyl-CpG-binding protein 2 polymorphisms and vulnerability to autism. Genes Brain Behav. 7(7), 754-760 (2008).
86. Nagarajan RP, Hogart AR, Gwye Y, Martin MR, Lasalle JM. Reduced MeCP2 expression is frequent in autism frontal cortex and correlates with aberrant MECP2 promoter methylation. Epigenetics 1(4), e1-e11 (2006).
87. Shibayama A, Cook EH Jr, Feng J et al. MECP2 structural and 3'-UTR variants in schizophrenia, autism and other psychiatric diseases: A possible association with autism. Am. J. Med. Genet. B Neuropsychiatr. Genet. 128B(1), 50-53 (2004).
88. Ramocki MB, Peters SU, Tavyev YJ et al. Autism and other neuropsychiatric symptoms are prevalent in individuals with MeCP2 duplication syndrome. Ann. Neurol. 66(6), 771-782 (2009).
89. Muller HM, Fiegl H, Goebel G et al. MeCP2 and MBD2 expression in human neoplastic and non-neoplastic breast tissue and its association with oestrogen receptor status. Br. J. Cancer 89(10), 1934-1939 (2003).
90. Cukier HN, Rabionet R, Konidari I et al. Novel variants identified in methyl-CpG-binding domain genes in autistic individuals. Neurogenetics 11(3), 291-303 (2010).
91. Liu H, Jin G, Wang H et al. Methyl-CpG binding domain 1 gene polymorphisms and lung cancer risk in a Chinese population. Biomarkers 13(6), 607-617 (2008).
92. Bader S, Walker M, Mcqueen HA et al. MBD1, MBD2 and CGBP genes at chromosome 18q21 are infrequently mutated in human colon and lung cancers. Oncogene 22(22), 3506-3510 (2003).
93. Jang JS, Lee SJ, Choi JE et al. Methyl-CpG binding domain 1 gene polymorphisms and risk of primary lung cancer. Cancer Epidemiol. Biomarkers Prev. 14(11 Pt 1), 2474-2480 (2005).
94. Ghersi D, Singh M. Interaction-based discovery of functionally important genes in cancers. Nucleic Acids Res. 42(3), e18 (2014).
95. Xu J, Zhu W, Xu W et al. Up-regulation of MBD1 promotes pancreatic cancer cell epithelial-mesenchymal transition and invasion by epigenetic down-regulation of E-cadherin. Curr. Mol. Med. 13(3), 387-400 (2013).
96. Xu J, Zhu W, Xu W et al. Silencing of MBD1 reverses pancreatic cancer therapy resistance through inhibition of DNA damage repair. Int. J. Oncol. 42(6), 2046-2052 (2013).
97. Patra SK, Patra A, Zhao H, Carroll P, Dahiya R. Methyl-CpG-DNA binding proteins in human prostate cancer: expression of CXXC sequence containing MBD1 and repression of MBD2 and MeCP2. Biochem. Biophys. Res. Commun. 302(4), 759-766 (2003).
98. Pontes TB, Chen ES, Gigek CO et al. Reduced mRNA expression levels of MBD2 and MBD3 in gastric carcinogenesis. Tumour Biol. 35(4), 3447-3453 (2014).
99. He M, Fan J, Jiang R, Tang WX, Wang ZW. Expression of DNMTs and MBD2 in GIST. Biomed. Rep. 1(2), 223-227 (2013).
100. Billard LM, Magdinier F, Lenoir GM, Frappart L, Dante R. MeCP2 and MBD2 expression during normal and pathological growth of the human mammary gland. Oncogene 21(17), 2704-2712 (2002).
101. Sapkota Y, Robson P, Lai R, Cass CE, Mackey JR, Damaraju S. A two-stage association study identifies methyl-CpGbinding domain protein 2 gene polymorphisms as candidates for breast cancer susceptibility. Eur. J. Hum. Genet. 20(6), 682-689 (2012).
102. Zhu Y, Brown HN, Zhang Y, Holford TR, Zheng T. Genotypes and haplotypes of the methyl-CpG-binding domain 2 modify breast cancer risk dependent upon menopausal status. Breast Cancer Res. 7(5), R745-R752 (2005).
103. Zhu D, Hunter SB, Vertino PM, Van Meir EG. Overexpression of MBD2 in glioblastoma maintains epigenetic silencing and inhibits the antiangiogenic function of the tumor suppressor gene BAI1. Cancer Res. 71(17), 5859-5870 (2011).
104. Balada E, Ordi-Ros J, Serrano-Acedo S, Martinez-Lostao L, Vilardell-Tarres M. Transcript overexpression of the MBD2 and MBD4 genes in CD4+ T cells from systemic lupus erythematosus patients. J. Leukoc. Biol. 81(6), 1609-1616 (2007).
105. Qin HH, Zhu XH, Liang J et al. Associations between aberrant DNA methylation and transcript levels of DNMT1 and MBD2 in CD4+ T cells from patients with systemic lupus erythematosus. Australas. J. Dermatol. 54(2), 90-95 (2013).
106. Chen ZP, Gu DS, Zhou ZP et al. Decreased expression of MBD2 and MBD4 gene and genomic-wide hypomethylation in patients with primary immune thrombocytopenia. Hum. Immunol. 72(6), 486-491 (2011).
107. Zhao S, Choi M, Overton JD et al. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc. Natl Acad. Sci. USA 110(8), 2916-2921 (2013).
108. Schlegel J, Guneysu S, Mennel HD. Expression of the genes of methyl-binding domain proteins in human gliomas. Oncol. Rep. 9(2), 393-395 (2002).
109. Bader S, Walker M, Hendrich B et al. Somatic frameshift mutations in the MBD4 gene of sporadic colon cancers with mismatch repair deficiency. Oncogene 18(56), 8044-8047 (1999).
110. Riccio A, Aaltonen LA, Godwin AK et al. The DNA repair gene MBD4 (MED1) is mutated in human carcinomas with microsatellite instability. Nat. Genet. 23(3), 266-268 (1999).
111. Yamada T, Koyama T, Ohwada S et al. Frameshift mutations in the MBD4/MED1 gene in primary gastric cancer with high-frequency microsatellite instability. Cancer Lett. 181(1), 115-120 (2002).
112. Saito Y, Kanai Y, Sakamoto M, Saito H, Ishii H, Hirohashi S. Expression of mRNA for DNA methyltransferases and methyl-CpG-binding proteins and DNA methylation status on CpG islands and pericentromeric satellite regions during human hepatocarcinogenesis. Hepatology 33(3), 561-568 (2001).
113. Cukier HN, Lee JM, Ma D et al. The expanding role of MBD genes in autism: identification of a MECP2 duplication and novel alterations in MBD5, MBD6, and SETDB1. Autism Res. 5(6), 385-397 (2012).
114. Hamdan FF, Srour M, Capo-Chichi JM et al. De novo mutations in moderate or severe intellectual disability. PLoS Genet. 10(10), e1004772 (2014).
115. Mullegama SV, Rosenfeld JA, Orellana C et al. Reciprocal deletion and duplication at 2q23.1 indicates a role for MBD5 in autism spectrum disorder. Eur. J. Hum. Genet. 22(1), 57-63 (2014).
116. Jørgensen HF, Ben-Porath I, Bird AP. MBD1 is recruited to both methylated and nonmethylated CpGs via distinct DNA binding domains. Mol. Cell. Biol. 24(8), 3387-3395 (2004).
117. Zhao X, Ueba T, Christie BR et al. Mice lacking methyl-CpG binding protein 1 have deficits in adult neurogenesis and hippocampal function. Proc. Natl Acad. Sci. USA 100(11), 6777-6782 (2003).
118. Roloff TC, Ropers HH, Nuber UA. Comparative study of methyl-CpG-binding domain proteins. BMC Genomics 4(1), 1 (2003).
119. Gnanapragasam MN, Scarsdale JN, Amaya ML et al. p66Alpha-MBD2 coiled-coil interaction and recruitment of Mi-2 are critical for globin gene silencing by the MBD2-NuRD complex. Proc. Natl Acad. Sci. USA 108(18), 7487-7492 (2011).
120. Becker A, Allmann L, Hofstatter M et al. Direct homo-and hetero-interactions of MeCP2 and MBD2. PLoS ONE 8(1), e53730 (2013).
121. Ng HH, Zhang Y, Hendrich B et al. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat. Genet. 23(1), 58-61 (1999).
122. Hendrich B, Guy J, Ramsahoye B, Wilson VA, Bird A. Closely related proteins MBD2 and MBD3 play distinctive but interacting roles in mouse development. Genes Dev. 15(6), 710-723 (2001).
123. Saito M, Ishikawa F. The mCpG-binding domain of human MBD3 does not bind to mCpG but interacts with NuRD/Mi2 components HDAC1 and MTA2. J. Biol. Chem. 277(38), 35434-35439 (2002).
124. Petronzelli F, Riccio A, Markham GD et al. Investigation of the substrate spectrum of the human mismatch-specific DNA N-glycosylase MED1 (MBD4): fundamental role of the catalytic domain. J. Cell. Physiol. 185(3), 473-480 (2000).
125. Hendrich B, Hardeland U, Ng H-H, Jiricny J, Bird A. The thymine glycosylase MBD4 can bind to the product of deamination at methylated CpG sites. Nature 401(6750), 301-304 (1999).
126. Wong E, Yang K, Kuraguchi M et al. MBD4 inactivation increases C right-arrowT transition mutations and promotes gastrointestinal tumor formation. Proc. Natl Acad. Sci. USA 99(23), 14937-14942 (2002).
127. Laget S, Joulie M, Le Masson F et al. The human proteins MBD5 and MBD6 associate with heterochromatin but they do not bind methylated DNA. PLoS ONE 5(8), e11982 (2010).
128. Qin S, Min J. Structure and function of the nucleosomebinding PWWP domain. Trends Biochem. Sci. 39(11), 536-547 (2014).
129. Jung JS, Jee MK, Cho HT et al. MBD6 is a direct target of Oct4 and controls the stemness and differentiation of adipose tissue-derived stem cells. Cell. Mol. Life Sci. 70(4), 711-728 (2013).
130. Falandry C, Fourel G, Galy V et al. CLLD8/KMT1F is a lysine methyltransferase that is important for chromosome segregation. J. Biol. Chem. 285(26), 20234-20241 (2010).
131. Schultz DC, Ayyanathan K, Negorev D, Maul GG, Rauscher FJ, 3rd. SETDB1: A novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins. Genes Dev. 16(8), 919-932 (2002).
132. Jones MH, Hamana N, Nezu J, Shimane M. A novel family of bromodomain genes. Genomics 63(1), 40-45 (2000).
133. Loyola A, Tagami H, Bonaldi T et al. The HP1alpha-CAF1-SetDB1-containing complex provides H3K9me1 for Suv39-mediated K9me3 in pericentric heterochromatin. EMBO Rep. 10(7), 769-775 (2009).
134. Strohner R, Nemeth A, Jansa P et al. NoRC-A novel member of mammalian ISWI-containing chromatin remodeling machines. EMBO J. 20(17), 4892-4900 (2001).
135. Santoro R, Grummt I. Epigenetic mechanism of rRNA gene silencing: temporal order of NoRC-mediated histone modification, chromatin remodeling, and DNA methylation. Mol. Cell. Biol. 25(7), 2539-2546 (2005).
136. Cramer JM, Scarsdale JN, Walavalkar NM, Buchwald WA, Ginder GD, Williams DC. Probing the dynamic distribution of bound states for methyl-cytosine binding domains on DNA. J. Biol. Chem. 289(3), 1294-1302 (2013).
137. Fraga MF, Ballestar E, Montoya G, Taysavang P, Wade PA, Esteller M. The affinity of different MBD proteins for a specific methylated locus depends on their intrinsic binding properties. Nucleic Acids Res. 31(6), 1765-1774 (2003).
138. Hashimoto H, Liu Y, Upadhyay AK et al. Recognition and potential mechanisms for replication and erasure of cytosine hydroxymethylation. Nucleic Acids Res. 40(11), 4841-4849 (2012).
139. Valinluck V, Tsai HH, Rogstad DK, Burdzy A, Bird A, Sowers LC. Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). Nucleic Acids Res. 32(14), 4100-4108 (2004).
140. Spruijt CG, Gnerlich F, Smits AH et al. Dynamic readers for 5-(hydroxy) methylcytosine and its oxidized derivatives. Cell 152(5), 1146-1159 (2013).
141. Gabel HW, Kinde B, Stroud H et al. Disruption of DNA-methylation-dependent long gene repression in Rett syndrome. Nature doi:10.1038/nature14319 (2015) (Epub ahead of print).
142. Nestor CE, Ottaviano R, Reddington J et al. Tissue type is a major modifier of the 5-hydroxymethylcytosine content of human genes. Genome Res. 22(3), 467-477 (2012).
143. Chatagnon A, Perriaud L, Nazaret N et al. Preferential binding of the methyl-CpG binding domain protein 2 at methylated transcriptional start site regions. Epigenetics 6(11), 1295-1307 (2011).
144. Menafra R, Brinkman AB, Matarese F et al. Genome-wide binding of MBD2 reveals strong preference for highly methylated loci. PLoS ONE 9(6), e99603 (2014).
145. Skene PJ, Illingworth RS, Webb S et al. Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state. Mol. Cell 37(4), 457-468 (2010).
146. Mayer C, Schmitz KM, Li J, Grummt I, Santoro R. Intergenic transcripts regulate the epigenetic state of rRNA genes. Mol. Cell 22(3), 351-361 (2006).
147. Jeffery L, Nakielny S. Components of the DNA methylation system of chromatin control are RNA-binding proteins. J. Biol. Chem. 279(47), 49479-49487 (2004).
148. Grewal SI, Jia S. Heterochromatin revisited. Nat. Rev. Genet. 8(1), 35-46 (2007).
149. Brero A, Easwaran HP, Nowak D et al. Methyl CpG-binding proteins induce large-scale chromatin reorganization during terminal differentiation. J. Cell Biol. 169(5), 733-743 (2005).
150. Casas-Delucchi CS, Becker A, Bolius JJ, Cardoso MC. Targeted manipulation of heterochromatin rescues MeCP2 Rett mutants and re-establishes higher order chromatin organization. Nucleic Acids Res. 40(22), e176 (2012).
151. Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat. Rev. Genet. 10(5), 295-304 (2009).
152. Sakamoto Y, Watanabe S, Ichimura T et al. Overlapping roles of the methylated DNA-binding protein MBD1 and polycomb group proteins in transcriptional repression of HOXA genes and heterochromatin foci formation. J. Biol. Chem. 282(22), 16391-16400 (2007).
153. Minkovsky A, Sahakyan A, Rankin-Gee E, Bonora G, Patel S, Plath K. The MBD1-Atf7ip-Setdb1 pathway contributes to the maintenance of X chromosome inactivation. Epigenetics Chromatin 7, 12 (2014).
154. Singleton MK, Gonzales ML, Leung KN et al. MeCP2 is required for global heterochromatic and nucleolar changes during activity-dependent neuronal maturation. Neurobiol. Dis. 43(1), 190-200 (2011).
155. Shahbazian M, Young J, Yuva-Paylor L et al. Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. Neuron 35(2), 243-254 (2002).
156. Meehan RR, Lewis JD, Mckay S, Kleiner EL, Bird AP. Identification of a mammalian protein that binds specifically to DNA containing methylated CpGs. Cell 58(3), 499-507 (1989).
157. Magdinier F, Wolffe AP. Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia. Proc. Natl Acad. Sci. USA 98(9), 4990-4995 (2001).
158. Lin X, Nelson WG. Methyl-CpG-binding domain protein-2 mediates transcriptional repression associated with hypermethylated GSTP1 CpG islands in MCF-7 breast cancer cells. Cancer Res. 63(2), 498-504 (2003).
159. Zhao Q, Rank G, Tan YT et al. PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing. Nat. Struct. Mol. Biol. 16(3), 304-311 (2009).
160. Di Lorenzo A, Bedford MT. Histone arginine methylation. FEBS Lett. 585(13), 2024-2031 (2011).
161. Wang H, Huang ZQ, Xia L et al. Methylation of histone H4 at arginine 3 facilitating transcriptional activation by nuclear hormone receptor. Science 293(5531), 853-857 (2001).
162. Pal S, Vishwanath SN, Erdjument-Bromage H, Tempst P, Sif S. Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor-suppressor genes. Mol. Cell. Biol. 24(21), 9630-9645 (2004).
163. Becker PB, Workman JL. Nucleosome remodeling and epigenetics. Cold Spring Harb. Perspect. Biol. 5(9), a017905 (2013).
164. Song JZ, Stirzaker C, Harrison J, Melki JR, Clark SJ. Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells. Oncogene 21(7), 1048-1061 (2002).
165. Stirzaker C, Song JZ, Davidson B, Clark SJ. Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells. Cancer Res. 64(11), 3871-3877 (2004).
166. Pombo A, Dillon N. Three-dimensional genome architecture: players and mechanisms. Nat. Rev. Mol. Cell Biol. 16(4), 245-257 (2015).
167. Georgel PT, Horowitz-Scherer RA, Adkins N, Woodcock CL, Wade PA, Hansen JC. Chromatin compaction by human MeCP2. Assembly of novel secondary chromatin structures in the absence of DNA methylation. J. Biol. Chem. 278(34), 32181-32188 (2003).
168. Nikitina T, Shi X, Ghosh RP, Horowitz-Scherer RA, Hansen JC, Woodcock CL. Multiple modes of interaction between the methylated DNA binding protein MeCP2 and chromatin. Mol. Cell. Biol. 27(3), 864-877 (2007).
169. Stuss DP, Cheema M, Ng MK et al. Impaired in vivo binding of MeCP2 to chromatin in the absence of its DNA methylbinding domain. Nucleic Acids Res. 41(9), 4888-4900 (2013).
170. Horike S, Cai S, Miyano M, Cheng JF, Kohwi-Shigematsu T. Loss of silent-chromatin looping and impaired imprinting of DLX5 in Rett syndrome. Nat. Genet. 37(1), 31-40 (2005).
171. Nan X, Hou J, Maclean A et al. Interaction between chromatin proteins MECP2 and ATRX is disrupted by mutations that cause inherited mental retardation. Proc. Natl Acad. Sci. USA 104(8), 2709-2714 (2007).
172. Rountree MR, Bachman KE, Baylin SB. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat. Genet. 25(3), 269-277 (2000).
173. Shibahara K, Stillman B. Replication-dependent marking of DNA by PCNA facilitates CAF-1-coupled inheritance of chromatin. Cell 96(4), 575-585 (1999).
174. Lu Y, Loh YH, Li H et al. Alternative splicing of MBD2 supports self-renewal in human pluripotent stem cells. Cell Stem Cell 15(1), 92-101 (2014).
175. Rais Y, Zviran A, Geula S et al. Deterministic direct reprogramming of somatic cells to pluripotency. Nature 502(7469), 65-70 (2013).
176. Shimoda N, Hirose K, Kaneto R et al. No evidence for AID/MBD4-coupled DNA demethylation in zebrafish embryos. PLoS ONE 9(12), e114816 (2014).
177. Cunha S, Lin YC, Goossen EA et al. The RON receptor tyrosine kinase promotes metastasis by triggering MBD4-dependent DNA methylation reprogramming. Cell Rep. 6(1), 141-154 (2014).
178. Pulukuri S, Rao JS. CpG island promoter methylation and silencing of 14-3-3σ gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2. Oncogene 25(33), 4559-4572 (2006).
179. Chatagnon A, Bougel S, Perriaud L, Lachuer J, Benhattar J, Dante R. Specific association between the methyl-CpGbinding domain protein 2 and the hypermethylated region of the human telomerase reverse transcriptase promoter in cancer cells. Carcinogenesis 30(1), 28-34 (2009).
180. Lopez-Serra L, Ballestar E, Fraga MF, Alaminos M, Setien F, Esteller M. A profile of methyl-CpG binding domain protein occupancy of hypermethylated promoter CpG islands of tumor suppressor genes in human cancer. Cancer Res. 66(17), 8342-8346 (2006).
181. Sansom OJ, Berger J, Bishop SM, Hendrich B, Bird A, Clarke AR. Deficiency of Mbd2 suppresses intestinal tumorigenesis. Nat. Genet. 34(2), 145-147 (2003).
182. Hodge JC, Mitchell E, Pillalamarri V et al. Disruption of MBD5 contributes to a spectrum of psychopathology and neurodevelopmental abnormalities. Mol. Psychiatry 19(3), 368-379 (2014).
183. Talkowski ME, Mullegama SV, Rosenfeld JA et al. Assessment of 2q23.1 microdeletion syndrome implicates MBD5 as a single causal locus of intellectual disability, epilepsy, and autism spectrum disorder. Am. J. Hum. Genet. 89(4), 551-563 (2011).
184. Williams SR, Mullegama SV, Rosenfeld JA et al. Haploinsufficiency of MBD5 associated with a syndrome involving microcephaly, intellectual disabilities, severe speech impairment, and seizures. Eur. J. Hum. Genet. 18(4), 436-441 (2010).
185. Cerami E, Gao J, Dogrusoz U et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2(5), 401-404 (2012).
186. Gao J, Aksoy BA, Dogrusoz U et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6(269), pl1 (2013).
187. Desai MA, Webb HD, Sinanan LM et al. An intrinsically disordered region of methyl-CpG binding domain protein 2 (MBD2) recruits the histone deacetylase core of the NuRD complex. Nucleic Acids Res. 43(6), 3100-3113 (2015).
188. The Cancer Genome Atlas (TCGA). http://cancergenome.nih.gov
189. cBioPortal for Cancer Genomics. www.cbioportal.org/public-portal/
190. cBioPortal for Cancer Genomics: MBD1. http://bit.ly/15Opeso
191. cBioPortal for Cancer Genomics: MBD2. http://bit.ly/1zR4Jou
192. cBioPortal for Cancer Genomics: MBD3. http://bit.ly/15OplEn
193. cBioPortal for Cancer Genomics: MBD4. http://bit.ly/1zgXlSs
194. cBioPortal for Cancer Genomics: MeCP2. http://bit.ly/1vkwzth
195. Miquel C, Jacob S, Grandjouan S et al. Frequent alteration of DNA damage signalling and repair pathways in human colorectal cancers with microsatellite instability. Oncogene 26(40), 5919-5926 (2007).
196. Khrapunov S, Warren C, Cheng H, Berko ER, Greally JM, Brenowitz M. Unusual characteristics of the DNA binding domain of epigenetic regulatory protein MeCP2 determine its binding specificity. Biochemistry (Mosc.) 53(21), 3379-3391 (2014).
197. Landau DA, Clement K, Ziller MJ et al. Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell 26(6), 813-825 (2014).